Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Discover how CDK4/6 inhibitors revolutionized HR+/HER2- metastatic breast cancer treatment in this expert analysis of the PALOMA-2 trial by Dr. Srinivas K G.

Speakers : Dr. Srinivas K G

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

Explore how CDK4/6 inhibitors are transforming HR+/HER2- advanced breast cancer treatment in post-menopausal women.

Speakers : Dr. Srinivas K G , Dr. Abhaya Kumar S M

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

Expert panel discussion on on the use of palbociclib in endocrine-resistant breast cancer. Learn about the clinical trial and optimize treatment strategies.

Speakers : Dr. Srinivas K G , Dr. Abhaya Kumar S M ,Dr. Vishwanath S

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

Join Dr. Srinivas K G, Dr. Abhaya Kumar S M, and Dr. Vishwanath S in a panel discussion on clinical trial endpoints for tumors with PPS > 12 months.

Speakers : Dr. Srinivas K G , Dr. Abhaya Kumar SM , Dr. Vishwanath S

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

Discover real-world clinical outcomes, key findings, and expert insights for optimizing patient care. Watch now for evidence-based oncology perspectives!

Speakers : Dr. Srinivas K G

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on the latest treatment strategies for relapsed/refractory adult B-cell ALL.

Speakers : Dr. Pawan Kumar Singh ,Dr. Roshan Dixit ,Dr. Manisha Jain ,Dr. Avruti Baweja

Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL

Renowned experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja discuss treatment goals for relapsed adult B-cell ALL, covering immunotherapy, targeted therapies,

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

Learn about CAR T-cell therapy, bispecific antibodies, and personalized treatment strategies. Watch now for cutting-edge recommendations!

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on Iontuzumab’s impact on CR/CRi rates and MRD negativity in leukemia.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Roshan Dikshit , Dr. Avriti Baveja

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

Explore the long-term survival outcomes of iontuzumab-treated patients in the INO-VATE trial with experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja


Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer during young adulthood carries long-term mental toll, study finds

2.

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

3.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

4.

Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.

5.

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot